← back to search

JiHoon Kang

Yonsei University · KR
Area of research
Pathology and Forensic Medicine · Cancer Research
Research interest
Research interests include Cancer Mechanisms and Therapy, Cancer, Hypoxia, and Metabolism, RNA modifications and cancer, and Pancreatic and Hepatic Oncology Research.
h-index
26
citations
2,059
works
117
NIH funding
primary concept
email

Recent publications

DGKB mediates radioresistance by regulating DGAT1-dependent lipotoxicity in glioblastoma
Cell Reports Medicine 2023cited by 33position: middledoi
Long non-coding RNA in glioma: novel genetic players in temozolomide resistance
Animal Cells and Systems 2023cited by 31position: middledoi
MALAT1-regulated gene expression profiling in lung cancer cell lines
BMC Cancer 2023cited by 27position: middledoi
Succinyl-CoA ligase ADP-forming subunit beta promotes stress granule assembly to regulate redox and drive cancer metastasis
Proceedings of the National Academy of Sciences 2023cited by 25position: middledoi
Mitochondrial glutamate transporter SLC25A22 uni-directionally export glutamate for metabolic rewiring in radioresistant glioblastoma
International Journal of Biological Macromolecules 2023cited by 25position: middledoi
Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies
Biomedicines 2022cited by 38position: middledoi
EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer
Cell Reports 2022cited by 33position: firstdoi
The Involvement of Long Non-Coding RNAs in Glutamine-Metabolic Reprogramming and Therapeutic Resistance in Cancer
International Journal of Molecular Sciences 2022cited by 25position: middledoi
Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1
Nature Communications 2021cited by 61position: middledoi
DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling
Clinical Cancer Research 2020cited by 62position: middledoi
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation
Journal of Clinical Investigation 2019cited by 43position: middledoi
LDR-Induced miR-30a and miR-30b Target the PAI-1 Pathway to Control Adverse Effects of NSCLC Radiotherapy
Molecular Therapy 2018cited by 34position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 6 papers (2018–2023)Sumin Kang · Emory Healthcare5 papers (2019–2023)Chaoyun Pan · Sun Yat-sen University5 papers (2019–2023)Austin C. Boese · Emory University5 papers (2019–2023)Kelly R. Magliocca · Emory University4 papers (2019–2023) · 4 papers (2018–2023)Lingtao Jin · Kennedy Krieger Institute3 papers (2019–2023) · 3 papers (2022–2023) · 3 papers (2022–2023) · 3 papers (2022–2023) · 3 papers (2022–2023) · 3 papers (2022–2023) · 3 papers (2022–2023)Jung Seok Hwang · Emory Healthcare3 papers (2021–2023)Anna D. Umano · Duke University2 papers (2019–2020)Dong M. Shin · Emory Healthcare2 papers (2019–2021) · 2 papers (2022–2023)Sagar Lonial · Emory University2 papers (2019–2020)Nabil F. Saba · Emory University2 papers (2019–2021)Courteney M. Malin · Emory University2 papers (2022–2023)